(NURO) NeuroMetrix Partners for Diabetes

Nerve testing devices maker NeuroMetrix (NURO) has partnered with Florida-based leading diabetes management products maker Nipro Diagnostics for its latest test, the NC-stat DPNCheck. The NC-stat DPNCheck test has been designed for evaluating systemic neuropathies such as diabetic peripheral neuropathy (“DPN”).

Nipro Diagnostics, a wholly-owned subsidiary of Japan-based Nipro Corporation Inc, offers high-quality blood glucose monitoring products and systems globally. The collaboration (between NeuroMetrix and Nipro) will focus on evaluating the opportunities for the novel NC-stat DPNCheck test in the rapidly growing retail medical clinic market.

DPN, a common and serious complication of diabetes, affects roughly 60%-70% of diabetics and may lead to foot ulcers and amputations. Currently, there is a lack of standardized test for DPN at the point-of-care, triggering a large unmet need.

NC-stat DPNCheck is a modified version of NeuroMetrix’s popular NC-stat device for detecting DPN. The companies feel that this new point-of-care device will help in the early detection, confirmation, and monitoring of DPN in a cost-effective manner, thereby addressing the need for a widely available, standardized test for DPN.

Retail medical clinics are among the fastest growing segments of the U.S. healthcare system, offering urgent, convenient medical care including vaccinations, treatment of minor injuries/chronic conditions and diagnostic procedures (including blood tests). These services generally cost less than similar services offered at physician offices or emergency departments.

These clinics are typically located in drug stores and other retail chain stores such as Wal-Mart (WMT) and Target (TGT). Currently, there are roughly 1,200 retail medical clinics across the U.S., a number which is growing at a double-digit clip annually.

NeuroMetrix plans to launch NC-stat DPNCheck at the annual conference of the American Diabetes Association (“ADA”) during June 24-28, 2011 with evaluation and commercial use expected to commence in third-quarter 2011.

NeuroMetrix develops and markets devices that help physicians detect and treat diseases and peripheral nerve injuries, and offer regional anesthesia and pain control. The company’s principal products are ADVANCE and NC-stat devices for nerve conduction study (“NCS”). NeuroMetrix competes with Medtronic (MDT) among others.

NeuroMetrix, in January 2011, modified its operational focus in favor of diabetes, in particular the diagnosis and monitoring of DPN. Moreover, the company, in March 2011, established a scientific advisory board for its new DPN test. The board consists of eminent international experts who will work closely with the company for improving detection, monitoring and management of DPN.

MEDTRONIC (MDT): Free Stock Analysis Report

NEUROMETRIX INC (NURO): Free Stock Analysis Report

TARGET CORP (TGT): Free Stock Analysis Report

WAL-MART STORES (WMT): Free Stock Analysis Report

Zacks Investment Research

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.


Powered by Facebook Comments

Similar Posts: | | | | | | | | Healthcare

RSS feeds: MDT | Medtronic Inc | Neurometrix Inc | NURO | Target Corporation | TGT | Wal-Mart Stores Inc. | WMT | Healthcare |

Other Posts by | RSS Feed for this author